Back to top
more

89BIO (ETNB)

(Real Time Quote from BATS)

$8.42 USD

8.42
266,234

+0.16 (1.94%)

Updated Apr 29, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ETNB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

89BIO [ETNB]

Reports for Purchase

Showing records 1 - 20 ( 25 total )

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 1

03/27/2024

Daily Note

Pages: 3

Pegozafermin Receives PRIME Status From EMA For MASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 2

03/13/2024

Daily Note

Pages: 3

Phase 3 ENLIGHTEN-Fibrosis Trial Kicks Off; ENLIGHTENCirrhosis Initiation on Target in 2Q24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 3

03/01/2024

Daily Note

Pages: 6

4Q Recap; Pegozafermin ENLIGHTEN Phase 3 MASH Program to Begin Within Weeks

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 4

01/23/2024

Industry Report

Pages: 6

Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 5

12/20/2023

Company Report

Pages: 7

Phase 3 ENLIGHTEN Program of PGZ to Start in 1H24; Model Updates Following Equity Raise; PT to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 6

12/05/2023

Daily Note

Pages: 4

Pegozafermin''s Phase 3 NASH Program Aligned With the FDA and EMA; First of Two Studies to Begin in 1Q24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 7

11/28/2023

Daily Note

Pages: 6

Phase 2b ENLIVEN Week 48 Dataset Extends Week 24 Findings

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 8

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for ETNB 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 9

11/10/2023

Company Report

Pages: 8

3Q Recap; Final Pegozafermin Phase 3 Program Design Expected in 4Q23 to Enable 1H24 Initiation; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 10

09/21/2023

Daily Note

Pages: 3

Pegozafermin Granted Breakthrough Therapy Designation; Planned Discussions to Finalize Phase 3 Design in 4Q; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 11

08/10/2023

Company Report

Pages: 9

2Q Recap: Regulatory Discussions on Phase 3 Path for NASH Planned for 2H23; Phase 3 ENTRUST Study Continues to Enroll

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 12

05/23/2023

Daily Note

Pages: 3

Phase 3 ENTRUST Trial Initiated; SHTG Safety Data Could Be Part of NASH Registrational Package; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 13

05/08/2023

Company Report

Pages: 6

1Q Recap; Phase 3 SHTG Study Initiates in 2Q23; Adding NASH Cirrhosis to our Model; Increasing PT to $35; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 14

03/22/2023

Company Report

Pages: 11

ENLIVEN''ing the ETNB Shares With Broad, Unequivocally Robust and Definitive PoC Results in NASH; Raise PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 15

03/20/2023

Company Report

Pages: 10

Our Take: Imminent NASH Catalyst to ENLIVEN the Shares For One of Our Top Picks; Affirm Buy, Moderate PT to $25

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 16

02/07/2023

Daily Note

Pages: 110

HCW 2023 Top Picks: Seize the Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 17

11/21/2022

Company Report

Pages: 9

3Q Recap: Phase 2b NASH Data Due in 1Q23; Primary Histology Endpoints to Be Read via Three-Panel Consensus; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 18

08/18/2022

Daily Note

Pages: 4

Phase 2b ENLIVEN NASH Trial Completes Enrollment; Top-Line Data Readout On Target For 1Q23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 19

08/17/2022

Company Report

Pages: 8

2Q Recap: ENTRIGUE Data at ESC Congress; SHTG Phase 3 Start 1H23; Phase 2b NASH Readout 1Q23; PT Up to $27

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: 89BIO

Industry: Medical - Biomedical and Genetics

Record: 20

07/27/2022

Company Report

Pages: 10

ENTRIGUE Data Significantly Exceeds Expectations; Disease- Modifying Profile Offers SoC Potential; PT to $26 on Dilution

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party